Abstract: Lithium is considered the first-line treatment in bipolar disorder, although response could range from an excellent response to a complete lack of response. Response to lithium is a complex phenotype in which different factors, part of them genetics, are involved. In this sense, the aim of this study was to investigate the potential association of genetic variability at genes related to phosphoinositide, glycogen synthetase kinase-3 (GSK3), hypothalamic-pituitary-adrenal, and glutamatergic pathways with lithium response. A sample of 131 bipolar patients (99 type I, 32 type II) were grouped and compared according to their level of response: excellent responders (ER), partial responders (PR), and nonresponders (NR). Genotype and allele distributions of the rs669838 (IMPA2), rs909270 (INNP1), rs11921360 (GSK3B), and rs28522620 (GRIK2) polymorphisms significantly differed between ER, PR, and NR. When we compared the ER versus PR+NR, the logistic regression showed significant association for rs669838-C (IMPA2; P = 0.021), rs909270-G (INPP1; P = 0.009), and rs11921360-A (GSK3B; P = 0.004) with lithium nonresponse. Haplotype analysis showed significant association for the haplotypes rs3791809-rs4853694-rs909270 (INPP1) and rs1732170-rs11921360-rs334558 (GSK3B) and lithium response. Our study is in line with previous studies reporting association between genetic variability at these genes and lithium response, pointing to an effect of IMPA2, INPP1, and GSK3B genes to lithium response in bipolar disorder patients. Further studies with larger samples are warranted to assess the strength of the reported associations.
L ithium (Li) is still considered the first-line treatment in bipolar disorder (BD) due to its proven efficacy in both acute and maintenance phases. 1, 2 However, an adequate response may range from an excellent response in 24% to 45% to a complete lack of response in 10% to 30% of patients. 3 Bipolar disorder is a complex disease that involves abnormalities at neuroprotective, neurochemical, neuroendocrinological, neurostructural, and genetic levels. 4, 5 Although Li is thought to target these altered levels, the precise genetic and molecular mechanism for its therapeutic action remains elusive. In addition, Li's responsiveness is also considered a complex phenotype. Thus, apart from genetic factors, others such as sociodemographic or clinical should be considered to understand clinical response. 6, 7 Evidence from molecular biology has shown that Li exerts multiple effects on neurotransmitter/receptor-mediated signaling, ion transport, signal transduction cascades, hormonal, and circadian regulation. It also profoundly alters gene expression patterns with a final effect stabilizing neuronal activities, supporting neural plasticity, and providing neuroprotection. 8 In this regard, intense interest has been focused upon the 2 major cell-signaling pathways with which Li interacts-phosphoinositide (PI) and glycogen synthetase kinase-3 (GSK3) pathways. However, other systems have been also involved. 7, 9, 10 In this sense, it is known that chronic Li administration upregulates glutamate reuptake, decreasing glutamate availability in synapse that could contribute to neuroprotective effect attributed to this drug. 11 Moreover, it has been demonstrated that Li leads to a significant activation of the hypothalamic-pituitary-adrenal (HPA) system in patients with major depression, rising CRH-stimulated parameters in the DEX/CRH test. 12 Identifying such a Li-responsive gene network in the brain would allow us to distinguish between subsets of genes underlying therapeutic and nontherapeutic actions of Li. The aim of this study was to investigate the potential association of genetic variability at 16 candidate genes related to PI (INPP1, MARCKS, IMPA1, IMPA2, ITPKC, PLCG1), GSK3 (GSK3B, GSK3A, CREB1), HPA (FKBP5, CRHR2, CRHR1), and glutamatergic (GRIA2, GABRB2, GRIK2, GRIK5) systems with Li response in BP.
MATERIALS AND METHODS
One hundred thirty-one unrelated white bipolar type I (n = 99) or II (n = 32) outpatients (69 males and 62 females) were recruited from the Bipolar Disorder Program (BDP) at the Hospital Clinic of Barcelona (n = 104) and from primary care settings in Oviedo (n = 27). The BDP has conducted a prospective data collection on course of illness of all patients in the program since 1992 as previously described. 13, 14 This cross-sectional analysis includes some variables from both prospective and retrospective assessments.
Inclusion criteria were as follows: (a) bipolar I or II Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision diagnosis; (b) age older than 18 years; (c) fulfilling criteria for euthymia defined as a score less than or equal to 8 on the Hamilton Depression Rating Scale 15 and a score less than or equal to 6 on the Young Mania Rating Scale 16 ; (d) all patients must receive or have received for at least 1 year Li as maintenance treatment therapy with doses adjusted to obtain plasma levels within the standard therapeutic range; and (e) written informed consent. Exclusion criteria were the presence of (a) mental retardation (defined as IQ <70), (b) severe organic disease, and (c) no tolerability to Li. All procedures were approved by each institution's ethics committees. All patients provided written informed consent for the collection of their data with research purposes, always preserving confidentiality.
Clinical and sociodemographic data were collected using a semistructured interview based on the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders and from available data in medical records. Suicidality was defined as the presence of any suicide ideation or previous suicide attempt.
The efficacy of Li treatment was assessed according to the following criteria: (a) excellent responders (ER), patients presenting a 50% reduction of the episodes after the introduction of Li in monotherapy; (b) partial responders (PR), patients presenting a 50% reduction of the episodes after the introduction of Li but on polytherapy (other mood stabilizer, antidepressant, or antipsychotics); and (c) nonresponders (NR), patients who did not reduce at least a 50% of the episodes and patients who required electroconvulsive therapy (adapted from Rybakowski et al 17 ). Candidate genes were selected, either on the basis of the mechanism of action of Li and/or the neurobiology of BD. Several single nucleotide polymorphisms (SNPs) at 16 common genes were selected according to previous literature and/or a tag SNP strategy allowed by the SYSNPS program (www.sysnps.org; Table 1 ). Genomic DNA was extracted from blood samples from each participant according to standard protocols. Genotyping, blind to clinical assessment, was performed by competitive quantitative PCR using allele-specific probes with FRET signal detection. A randomized 10% of individuals were regenotyped to confirm the pattern reproducibility.
Differences in sociodemographic and clinical variables between the groups of Li responders were evaluated with χ 2 test and 1-way analysis of variance as appropriate using SPSS v.18. EpiInfo v.3.5.1 was used to calculate Hardy-Weinberg equilibrium for genotype frequencies using χ 2 test. Genotype and allele association analyses between the groups of patients with different Li response (ER, PR, and NR) were performed using χ 2 test. As a second analysis, PR and NR were pooled together and compared with ER. Because suicidality significantly differed between the groups of responders ( cov+gen]) represents the increase in the variance explained attributable to the genotype. Empirical P values were generated using the max(T) permutation approach (10,000 permutations) for pointwise estimates (EMP1) as well as corrected for all comparisons (EMP2). Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated for the effects of high-risk genotypes. The study had an 80% power (95% CI) to detect OR in a range of 3.99 to 5.75 between genotypes for Li response (PR and NR pooled together) according to the range of obtained minor allele frequencies (0.5-0.1, respectively). All the analyses were carried out with PLINK, version 2.07. 18 Haploview 3.2 was used to generate a linkage disequilibrium map. Haplotype analyses were conducted using the 'R' software (v.2.2.1) by the "haplo.stat" package. Suicidality was included in the haplotype analyses as a covariate. Rare haplotypes, those which were less frequent than 1%, were excluded from the analyses. The global significance of the results for haplotype analyses was estimated using permutation (50,000 permutations) to confirm the asymptotic P values.
RESULTS
Twenty-six patients (19.8%) were classified as ER, 62 patients (47.3%) as PR, and 43 patients (32.8%) as NR to Li treatment.
Sociodemographic and clinical features of the sample are shown in Table 2 . No differences for mean age, age at onset, sex, type of BD, duration of Li treatment, or family history of psychiatric illness were found when comparing patients according to their level of Li response. Significantly differences in suicidality were found between the groups of responders. Nonresponders presented higher rates of suicidality than PR or ER (P < 0.001). Suicidality was included as a covariate in the logistic regression and haplotype analyses.
Genotype distributions of the SNPs were all in HardyWeinberg equilibrium (data not shown).
Significant differences were found in genotypic and allelic distributions between different groups of Li responders for the rs669838 (IMPA2) (genotype: χ 2 = 10.338, df = 4, P = 0.035; allele: χ 2 =8.51,df=2,P= 0.015),rs909270 (INNP1)(genotype:χ 2 =10.132, df = 4, P = 0.038; allele: χ 2 = 6.51, df = 2, P = 0.038), rs11921360 (GSK3B) (genotype: χ 2 = 9.713, df = 4, P = 0.046; allele: χ 2 = 8.51, df = 2, P = 0.0057), and rs28522620 (GRIK2) (genotype: χ 2 = 9.597, df = 4, P = 0.048; allele: χ 2 = 8.25, df = 2, P = 0.016) polymorphisms (see Supplementary Table 1 , Supplemental Digital Content 1, http://links.lww.com/JCP/A310, for details of genotype and allele distributions). P values were not significant after permutation testing. No other associations were found regarding the other SNPs analyzed.
When we pooled together PR+NR versus ER and compared the SNPs associated in our previous association analyses, logistic regression showed significant association for rs669838 (IMPA2) (P = 0.021; R Haplotype analysis showed an association of rs3791809-rs4853694-rs909270 haplotype in INPP1 (D' = 0.94, r 2 = 0.43) and Li response. Frequencies of the T-A-G haploblock were more frequent in PR+NR (0.488) than in ER group (0.306) (P = 0.012; sim P = 0.012). On the contrary, T-A-A haploblock was more frequent in ER than in PR+NR group (0.241 vs 0.12) (P = 0.018; sim P = 0.019). The rs1732170-rs11921360-rs334558 haplotype in GSK3B (D' = 0.979, r 2 = 0.742) was also associated with Li response (global P = 0.002, global sim P = 0.002). The C-C-A haploblock was significantly less frequent in the group of PR +NR (0.299) than in ER (0.552) (P = 0.001; sim P = 0.001). No other significant associations were found regarding the remaining analyzed haplotypes and Li response.
DISCUSSION
This study analyzed the potential association of genetic variability at PI, GSK3, HPA, and glutamatergic pathways with Li response in BD.
A large number of studies tried to identify genetic variants within genes of PI system, which could predict response to Li. However, the results are still controversial making unclear the role of this system in Li response. 19 Our results are in line with these studies reporting an effect of genetic variability at this system and Li response. Particularly, we found the effect of rs669838 (IMPA2) and rs909270 (INNP1). The IMPA2 gene is located in a region thought to be a BD susceptibility locus (18p11.2). 20 Two trends for association have been previously found between 2 polymorphisms (rs3786282 and 599+97G>A) of this gene and good response to Li in BD patients. 21 The C937A variant of INPP1 was associated with response to Li in a Norwegian sample but not in an independent Israeli sample. 22 This finding was not supported in another study. 3 Regarding GSK3B, we found association with rs11921360 and Li response. Previously, a functional polymorphism of the GSK3B gene and Li response was reported, 23 but this was not confirmed in 2 other studies. 3, 24 Relatively few association studies have been conducted between glutamatergic system and Li response. Genetic variability at GRIN2B gene was examined and failed to predict Li outcome. 25 A recent genomewide association study showed that an SNP in the GluR2 gene was associated with the risk for recurrence among patients treated with Li. 26 In our study, the findings suggest that Li response seems to be associated with genetic variability at GRIK2 gene. The GRIK2 gene (6q.21), which encodes for a kainate receptor (GluR6) implicated in synaptic plasticity, 27 had been previously reported as candidate gene conferring a predisposition to BD. 27, 28 We did not found any association between response to Li and the genetic variants of the HPA system. Although no other studies investigating the role of the genes analyzed in the present study have been found, a previous report analyzing several genetic variability at the glucocorticoid receptor gene (NR3C1) showed association between this gene and Li response. 29 The results from the allele and genotype associations comparing the 3 different groups of Li responders (ER, PR, and NR) did not survive multiple testing in our sample. However, when we analyzed these SNPs comparing PR+NR versus ER, we found significant association surviving multiple testing for all of them except the polymorphism in the GRIK2 gene. Moreover, subsequent haplotype analyses, which are considered a more powerful genetic and statistical approach, were in the same direction of these previous associations supporting our findings.
Our study has some limitations. Because of the tertiary nature of the BDP, some of the subjects included in this study could be categorized as difficult-to-treat patients, thus generalization of our results should be done with caution. The relative small size of our sample limits the power to detect small differences. Moreover, all the variants associated in the present study are intron variants. It has been suggested that silent SNPs can affect in vivo splicing events or protein folding and, consequently, the final protein function. 30 Recent data from the ENCODE (Encyclopedia of DNA Elements) project have revealed the importance of intronic and intergenic variants as regulatory elements of gene expression acting as micro-RNAs and/or epigenetic targets. 31 Alternatively, these polymorphisms might not constitute the actual causative variant, but rather reflect association of other polymorphisms in linkage disequilibrium with this locus.
Pharmacogenetics may one day help to unravel the complexities of Li treatment response and also shed light on the mechanism of BD. However, the individual genetic makeup is not the only determinant of variable drug responses, which will provide information for just a part of the complex puzzle of clinical response to Li treatment. Other factors, such environment, sociodemographic, and clinical features, will be also necessary to understand the total phenotype. In this sense, pharmacogenetics will provide relative and probabilistic information; in any case, it would be absolute or deterministic. 32 Our results, representing a small piece of the complexity of Li response, support previous data involving PI system in Li response. However, evidence is still far from being useful in clinical practice.
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